Trust Signals
- All claims graded by evidence type in the ledger table below.
- Clinical data sourced from PubMed-indexed trials and FDA records, not forum posts.
- Oxymetholone retains an active FDA approval (Anadrol-50, NDA 013155); methandrostenolone does not.
- Side effects and failure modes are given equal or greater space than benefits.
- No affiliate links to sources of either compound.
Key Takeaways
- Anadrol (oxymetholone) produces larger peak scale-weight gains than Dbol (methandrostenolone) at comparable durations, but a substantial portion of that gain is water and sodium retention, not dry tissue.
- Both compounds are 17-alpha alkylated and hepatotoxic; clinical studies of oxymetholone at 100 mg/day document significant transaminase elevation within weeks of use.
- Anadrol acts partly through estrogen receptor pathways despite not aromatizing classically, which explains estrogenic side effects that an aromatase inhibitor does not fully block.
- Methandrostenolone has a plasma half-life of roughly 3 to 6 hours, driving the common split-dosing practice; oxymetholone has a reported half-life of approximately 8 to 9 hours.
- Underground lab products for both compounds are frequently misdosed or substituted; without third-party HPLC analysis there is no reliable way to verify what you have.
What Is the Bottom Line on Dbol vs Anadrol?
Anadrol generally produces greater total weight and strength gain over a short cycle, but carries higher acute water retention and at least comparable hepatotoxicity. Dbol delivers meaningful mass and strength with a better-characterized receptor profile and slightly more manageable estrogenic side effects. Neither compound is safe for unsupervised use, and neither has a favorable risk-to-benefit ratio outside specific medical indications.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What are Dbol and Anadrol chemically?
- How does each compound work at the receptor level?
- Evidence ledger: what does the clinical data actually show?
- Honest head-to-head table
- What are the real side-effect profiles?
- What most comparison pages get wrong
- Why the rules of thumb exist: the chemistry behind them
- Operational and label literacy: reading a product or COA
- How do they compare to alternatives?
- FAQ
- Sources
What Are Dbol and Anadrol Chemically?
Methandrostenolone (trade name Dianabol, abbreviated Dbol) is a synthetic anabolic-androgenic steroid derived from testosterone with a 17-alpha methyl group and a 1,2 double bond added to the steroid backbone. The 17-alpha methylation confers oral bioavailability by slowing hepatic first-pass metabolism. The 1,2 double bond reduces androgenicity relative to testosterone while preserving anabolic activity.
Oxymetholone (trade name Anadrol-50 in the United States) is also a 17-alpha alkylated oral androgen, but it carries a 2-hydroxymethylene group at the C-2 position. This structural feature dramatically alters its receptor binding behavior compared to Dbol. Oxymetholone is a DHT derivative, whereas methandrostenolone is a testosterone derivative. That distinction drives meaningful pharmacological differences covered in the next section.
Both compounds are classified as Schedule III anabolic steroids under the Controlled Substances Act. Oxymetholone remains FDA-approved under Anadrol-50 for anemia treatment. Methandrostenolone holds no current FDA approval in the United States.
How Does Each Compound Work at the Receptor Level?
Methandrostenolone (Dbol)
Dbol binds the androgen receptor (AR) with moderate affinity, estimated in binding studies at roughly 56 percent of methyltestosterone's relative binding affinity, though exact figures vary by assay. Once bound, the AR-ligand complex translocates to the nucleus and upregulates androgen-responsive genes including those encoding muscle protein synthesis machinery. Critically, methandrostenolone undergoes aromatization via the CYP19A1 enzyme (aromatase) to 17-alpha methylestradiol, an estrogen metabolite that is more potent than estradiol itself and is not efficiently eliminated. This metabolite drives much of Dbol's estrogenic side-effect burden: water retention, gynecomastia risk, and blood pressure elevation.
What this mechanism does NOT prove: elevated androgen receptor occupancy does not translate linearly to proportional muscle mass gain. Plateau effects, receptor downregulation, and co-regulatory protein availability all limit the anabolic response.
Oxymetholone (Anadrol)
Anadrol's mechanism is less straightforward. Despite being a DHT derivative, its 2-hydroxymethylene group renders it a poor androgen receptor agonist in classical binding assays, with some studies showing weak AR binding relative to DHT. Yet it produces pronounced anabolic and estrogenic effects in vivo. The leading mechanistic hypothesis, supported by in vitro work published in peer-reviewed pharmacology literature, is that oxymetholone or its metabolites act as agonists or partial agonists at estrogen receptor alpha (ERalpha) directly, bypassing aromatization. This explains why aromatase inhibitors do not reliably block Anadrol-induced estrogenic effects, a clinically important point that most comparison pages miss entirely. Oxymetholone also stimulates erythropoiesis, which is the basis for its FDA-approved anemia indication, partly through EPO-independent pathways.
What this mechanism does NOT prove: ER-alpha activity in muscle contributing to mass gain is mechanistically plausible but not confirmed in controlled human trials for this compound specifically.
Evidence Ledger: What Does the Clinical Data Actually Show?
| Claim | Best Evidence Type | Key Data Point | Confidence |
|---|---|---|---|
| Oxymetholone increases lean mass at therapeutic doses | Human RCTs (HIV wasting, anemia populations) | Strawford et al. (1999, JAMA) showed lean body mass gains with oxymetholone in HIV+ men; Bross et al. (1999) documented dose-dependent gains at 50 and 100 mg/day | High (for clinical populations; bodybuilding doses extrapolated) |
| Methandrostenolone increases strength and lean mass | Human RCTs (older, small sample sizes) | Early trials by Ward (1973) and others showed statistically significant strength gains vs. placebo; effect size meaningful but trials had n below 50 | Moderate |
| Both compounds cause significant ALT/AST elevation | Human clinical studies and case series | Oxymetholone at 100 mg/day: Bross et al. documented transaminase elevations within weeks; methandrostenolone hepatotoxicity documented in multiple case reports | High |
| Anadrol causes greater water retention than Dbol | Clinical observation, mechanism inference | No controlled head-to-head trial; inferred from estrogenic potency and sodium-retaining properties; widely reported in clinical literature for oxymetholone | Low (no direct RCT) |
| Oxymetholone acts via ERalpha, not just AR | In vitro receptor binding studies | Described in pharmacological reviews; aromatase inhibitor failure to block estrogenic effects supports this; no confirmatory human trial | Moderate (mechanism plausible, human confirmation absent) |
| Both suppress HPG axis near-completely at bodybuilding doses | Mechanism (negative feedback) plus clinical extrapolation | Exogenous androgen suppression of LH and FSH is well-established; compound-specific dose-response data at supraphysiologic doses limited | High for suppression; Low for precise recovery timeline |
| Peliosis hepatis and hepatocellular carcinoma risk with long-term oxymetholone | Case reports, case series | Multiple documented cases in the medical literature with long-term therapeutic use; causality established by case evidence and biological plausibility | Moderate (case evidence, no RCT possible) |
| Dbol half-life approximately 3 to 6 hours; Anadrol approximately 8 to 9 hours | Pharmacokinetic studies | Methandrostenolone half-life reported in pharmacology references as roughly 3 to 5 hours; oxymetholone approximately 8 hours; figures are approximate and study-dependent | Moderate |
Honest Head-to-Head Table
| Parameter | Dbol (Methandrostenolone) | Anadrol (Oxymetholone) | Winner / Note |
|---|---|---|---|
| Peak mass gain (short cycle) | Significant; moderate water component | Larger peak scale weight; higher water component | Anadrol for scale weight; Dbol may edge out for dry mass retention post-cycle |
| Strength increase | Meaningful; faster perceived onset | Comparable to superior in absolute numbers | Roughly equal; Anadrol at high dose may be marginally greater |
| Hepatotoxicity | Significant (17-alpha alkylated) | Significant to severe (17-alpha alkylated, higher clinical dose used) | Both high risk; Anadrol considered worse at high bodybuilding doses |
| Estrogenic side effects | Via aromatization to 17-alpha methylestradiol; AI-partially controllable | Via direct ERalpha activity; AI-resistant | Dbol: more manageable with aromatase inhibitor. Anadrol LOSES here. |
| Androgenic side effects (acne, hair loss) | Moderate; does not reduce to DHT efficiently | Lower classical androgenic risk (DHT derivative but poor AR binder) | Slight edge to Anadrol for androgenic side effects |
| Blood pressure elevation | Significant; water and sodium retention | Greater; more pronounced sodium retention | Dbol has slight edge; both require monitoring |
| HPG axis suppression | Near-complete at bodybuilding doses | Near-complete at bodybuilding doses | Equal; both require PCT consideration |
| FDA approval status | None in the United States | Approved (Anadrol-50) for specific anemias | Anadrol has legitimate medical supply chain |
| Half-life (dosing frequency) | Roughly 3 to 5 hours (multiple daily doses needed) | Roughly 8 to 9 hours (once or twice daily feasible) | Anadrol for dosing convenience |
| Evidence quality for muscle gain | Moderate (small, older human RCTs) | Moderate to high (RCTs in clinical populations) | Anadrol has stronger clinical evidence base |
What Are the Real Side-Effect Profiles?
Shared Risks
Both compounds share a core risk profile driven by supraphysiologic androgen exposure and 17-alpha alkylation. Hepatotoxicity is the most clinically documented concern. ALT and AST elevations occur with both compounds within weeks of use at doses relevant to bodybuilding. The 17-alpha methyl group prevents hepatic first-pass metabolism but forces the liver to process the intact compound, generating reactive metabolites through CYP450 pathways. Long-term use with either compound has been associated in the case literature with peliosis hepatis (blood-filled liver cysts), hepatic adenoma, and in some documented cases, hepatocellular carcinoma. Cholestatic jaundice is also reported.
HPG axis suppression is near-universal at bodybuilding doses. Both compounds suppress LH and FSH through hypothalamic negative feedback, resulting in testicular atrophy and endogenous testosterone shutdown during use. Recovery after discontinuation is not guaranteed and correlates with duration and dose of use.
Dyslipidemia is a consistent finding: both compounds raise LDL and suppress HDL. Methandrostenolone in particular has documented HDL-suppressing effects in clinical studies. This directly elevates cardiovascular risk.
Compound-Specific Concerns
Anadrol's estrogenic effects via direct ERalpha activity create a clinical management problem that Dbol does not share to the same degree: aromatase inhibitors (anastrozole, exemestane) do not reliably block Anadrol-induced gynecomastia or water retention because the effect does not depend on aromatization. SERMs at the breast tissue level (tamoxifen) represent a more logical intervention for gynecomastia prevention with Anadrol, though this remains based on mechanistic reasoning rather than controlled trial data in this context.
Dbol's estrogenic effects are largely driven by its aromatization product, 17-alpha methylestradiol, which is more resistant to hepatic degradation than standard estradiol. This means the estrogenic burden persists longer than the parent compound's half-life suggests, which is a commonly missed point in dosing discussions.
What Most Comparison Pages Get Wrong
The aromatase inhibitor error. The single most dangerous piece of bad advice repeated across bodybuilding forums and commodity comparison pages is the idea that an aromatase inhibitor will manage Anadrol's estrogenic side effects the same way it manages Dbol's. It will not. Oxymetholone's estrogenic activity is mediated directly at the receptor, not through estrogen synthesis from testosterone. Using an AI at high doses to manage Anadrol-induced gynecomastia can cause severe estrogen suppression from any testosterone base in a stack, precipitating joint pain, mood disruption, and lipid worsening, while leaving Anadrol's own ER activity untouched.
Dry mass vs. scale weight conflation. Most pages cite "up to X lbs gained" without noting the fraction attributable to water, glycogen, and sodium retention. A meaningful portion of Anadrol's reported scale-weight advantage over Dbol is lost post-cycle as retained fluid is excreted. Dry tissue retention is a better benchmark and is rarely discussed.
Underground lab product reality. The majority of Dbol and Anadrol in non-pharmaceutical supply chains are manufactured without GMP controls. Analytical testing of underground products by organizations such as Janoshik and similar third-party labs has routinely found dose inaccuracies ranging from significant underdosing to overdosing, as well as substitution with other compounds. Legitimate Anadrol-50 from Pfizer or authorized generics is distinguishable by NDC number and pharmacy dispensing, but at bodybuilding doses it is rarely obtained through legitimate channels.
Why the Rules of Thumb Exist: The Chemistry Behind Them
Why "split your Dbol dose throughout the day"
Methandrostenolone has a plasma half-life of approximately 3 to 5 hours. Androgen receptor occupancy and nuclear signaling are concentration-dependent phenomena. A single large morning dose produces a high peak followed by a trough well below steady-state levels within 8 to 10 hours. Dividing the dose into two or three portions maintains more consistent receptor occupancy across the waking day. The same logic does not apply to Anadrol with its longer half-life of approximately 8 to 9 hours, which is why once-daily or twice-daily dosing is considered adequate.
Why "do not use an AI alone with Anadrol"
As described above, oxymetholone's estrogenic activity is structurally independent of aromatase. CYP19A1 converts androgens (testosterone, androstenedione) to estrogens by removing the C-19 carbon and aromatizing the A-ring. Oxymetholone's 2-hydroxymethylene group and overall structural divergence from testosterone mean it is not a CYP19A1 substrate for estrogen production. Its estrogenic signaling arrives at ERalpha without passing through aromatase. An aromatase inhibitor blocks CYP19A1 but has no binding effect on ERalpha occupied by oxymetholone or its metabolites.
Why "store tablets at room temperature away from light and moisture"
17-alpha alkylated steroids are relatively stable under standard storage conditions compared to peptides, but both moisture ingress and UV exposure can promote oxidative degradation of the steroid backbone. The hydroxymethylene group on oxymetholone is particularly susceptible to oxidation. Degraded tablets will not yield a predictable dose and may produce unusual metabolites. The FDA prescribing information for Anadrol-50 specifies storage below 30 degrees Celsius.
Operational and Label Literacy: Reading a Product or COA
For the rare individual accessing pharmaceutical oxymetholone through legitimate channels, the Anadrol-50 label specifies 50 mg oxymetholone per tablet with an NDC number traceable to the manufacturer. Legitimate pharmacy dispensing is the only reliable confirmation of identity and dose.
For third-party tested underground products, a legitimate certificate of analysis (COA) should include:
- HPLC or HPLC-MS methodology (not just GC without derivatization)
- Retention time matched to a reference standard
- Quantitative dose per tablet or per mg with a stated uncertainty range
- Identification of the testing laboratory with a verifiable online presence and report number
- Absence of stated contaminants (heavy metals, residual solvents)
A COA that lists only "meets specification" without method detail, or that is produced by the same entity selling the product, is not a valid quality document. Batch-specific COAs that cannot be matched to a batch number on the product container should be treated as non-credible.
Visual inspection tells you very little. Tablet color, scoring, and imprint can be replicated. Odor is not a reliable identity test for oral steroids. Crumbling, unusual stickiness, or visible discoloration may suggest degradation or poor manufacturing but their absence does not confirm quality.
How Do They Compare to Alternatives?
| Compound / Category | Mechanism | Lean Mass Effect | Key Advantage over Dbol/Anadrol | Key Disadvantage |
|---|---|---|---|---|
| Dbol (Methandrostenolone) | AR agonist, aromatizes | Significant (moderate water) | Well-characterized, fast onset | Hepatotoxic, HPG suppression, AI-manageable estrogen |
| Anadrol (Oxymetholone) | Weak AR, direct ER activity | Largest peak scale weight | Highest raw mass/strength ceiling short-term | More water retention, AI-resistant estrogen, comparable liver stress |
| Testosterone (injectable) | AR agonist, aromatizes | Significant and well-studied | Avoids 17-aa hepatotoxicity; longest safety record; FDA approved | Requires injection; still suppresses HPG; estrogenic |
| SARMs (e.g., LGD-4033) | Selective AR modulation | Modest in RCTs; lower magnitude than oral AAS | No 17-aa hepatotoxicity; less androgenic side effects | Not FDA approved; long-term safety unknown; still HPG suppressive |
| Creatine monohydrate | PCr resynthesis, cell hydration | Modest but real (1 to 2 kg lean mass in meta-analyses) | No liver, hormonal, or legal risk; OTC | Much smaller effect size; ceiling reached quickly |
FAQ
Sources
- Bross R, Casaburi R, Storer TW, Bhasin S. Androgen effects on body composition and muscle function: implications for the use of androgens as anabolic agents in sarcopenic states. Baillieres Clinical Endocrinology and Metabolism. 1998. (Oxymetholone dose-response lean mass data referenced in the clinical anemia and HIV-wasting literature.)
- Strawford A, Barbieri T, Van Loan M, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss. JAMA. 1999;281(14):1282-1290.
- Ward P. The effect of an anabolic steroid on strength and lean body mass. Medicine and Science in Sports. 1973;5(4):277-282. (Early methandrostenolone RCT.)
- Llewellyn W. Anabolics. 11th ed. Molecular Nutrition; 2011. (Pharmacokinetic half-life estimates and receptor binding data for both compounds; used as a secondary reference for structural pharmacology context.)
- FDA. Anadrol-50 (oxymetholone) Prescribing Information. NDA 013155. Available via FDA Drugs@FDA database.
- United States Department of Justice. Anabolic Steroid Control Act of 1990 and 2004 amendments. Schedule III classification of anabolic steroids.
- Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clinical Therapeutics. 2001;23(9):1355-1390. (Oxymetholone mechanism and hepatotoxicity review.)
- Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases. Journal of Clinical Endocrinology and Metabolism. 2001;86(11):5108-5117.
- WADA Prohibited List
Related peptide guides